Merck KGaA (FRA:MRK) Given a €100.00 Price Target by JPMorgan Chase & Co. Analysts
JPMorgan Chase & Co. set a €100.00 ($116.28) price target on Merck KGaA (FRA:MRK) in a report issued on Thursday morning, Borsen Zeitung reports. The brokerage currently has a neutral rating on the healthcare company’s stock.
A number of other equities research analysts have also recently weighed in on the company. Credit Suisse Group set a €110.00 ($127.91) price target on Merck KGaA and gave the company a buy rating in a report on Friday, September 6th. Kepler Capital Markets set a €108.00 ($125.58) price target on Merck KGaA and gave the company a buy rating in a report on Monday, June 17th. Morgan Stanley set a €96.00 ($111.63) price target on Merck KGaA and gave the company a neutral rating in a report on Tuesday. UBS Group set a €99.00 ($115.12) price target on Merck KGaA and gave the company a neutral rating in a report on Thursday, August 8th. Finally, DZ Bank reaffirmed a buy rating on shares of Merck KGaA in a report on Wednesday, August 14th. One research analyst has rated the stock with a sell rating, thirteen have issued a hold rating and five have assigned a buy rating to the company’s stock. Merck KGaA has a consensus rating of Hold and a consensus price target of €100.94 ($117.38).
Shares of MRK traded up €1.66 ($1.93) during mid-day trading on Thursday, reaching €99.02 ($115.14). 739,433 shares of the company’s stock traded hands. The business’s 50-day moving average price is €94.72 and its 200-day moving average price is €94.64. Merck KGaA has a 12 month low of €76.60 ($89.07) and a 12 month high of €115.00 ($133.72).
MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. It offers prescription medicines to treat cancer, multiple sclerosis, infertility, growth deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, as well as squamous cell carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments.
See Also: What Are Treasury Bonds?
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.